乳腺癌仍然是全球癌症死亡的一个重要原因，特别是在女性中。这凸显了早期发现和治疗在提高生存率方面的关键作用。虽然乳房 X 光检查、活检、超声波和 MRI 等传统诊断方法是有价值的工具，但在成本、侵入性以及对专业设备和训练有素的人员的需求方面存在局限性。最近向生物传感器技术的转变为监测生物过程并以经济高效、非侵入性的方式提供准确的健康诊断提供了一种有前景的替代方案。这些生物传感器对于原发肿瘤、转移瘤和复发性疾病的早期检测特别有利，有助于更有效的乳腺癌管理。将生物传感器技术集成到医疗设备中促进了低成本、适应性强且高效的诊断工具的开发。在此框架中，电化学筛选平台由于其选择性、经济性和易于结果解释而引起了极大的关注。当前的综述讨论了各种乳腺癌生物标志物以及电化学生物传感器彻底改变早期癌症检测的潜力，为新的诊断平台和个性化医疗保健解决方案提供了条件。版权所有 © 2024 Elsevier B.V. 保留所有权利。

Breast cancer continues to be a significant contributor to global cancer deaths, particularly among women. This highlights the critical role of early detection and treatment in boosting survival rates. While conventional diagnostic methods like mammograms, biopsies, ultrasounds, and MRIs are valuable tools, limitations exist in terms of cost, invasiveness, and the requirement for specialized equipment and trained personnel. Recent shifts towards biosensor technologies offer a promising alternative for monitoring biological processes and providing accurate health diagnostics in a cost-effective, non-invasive manner. These biosensors are particularly advantageous for early detection of primary tumors, metastases, and recurrent diseases, contributing to more effective breast cancer management. The integration of biosensor technology into medical devices has led to the development of low-cost, adaptable, and efficient diagnostic tools. In this framework, electrochemical screening platforms have garnered significant attention due to their selectivity, affordability, and ease of result interpretation. The current review discusses various breast cancer biomarkers and the potential of electrochemical biosensors to revolutionize early cancer detection, making provision for new diagnostic platforms and personalized healthcare solutions.Copyright © 2024 Elsevier B.V. All rights reserved.